SBIR-STTR Award

Mouth Barrier Rinse of Sustained-Release Poly(Curcumin) to Treat Oral Mucositis
Award last edited on: 1/29/18

Sponsored Program
SBIR
Awarding Agency
NIH : NIDCR
Total Award Amount
$1,568,324
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Nihar Manilal Shah

Company Information

Bluegrass Advanced Materials LLC (AKA: BAM)

145 Graham Avenue
Lexington, KY 40506
   (859) 333-7274
   jwyse@bgamaterials.com
   www.bgamaterials.com
Location: Single
Congr. District: 06
County: Fayette

Phase I

Contract Number: 1R43DE023523-01A1
Start Date: 9/24/13    Completed: 8/31/14
Phase I year
2013
Phase I Amount
$217,689
Every year in the United States, approximately 132,000 patients undergoing anti-cancer therapy develop oral mucositis (OM), a painful, debilitating oral wound condition, which is estimated to increase the patient's cost of care by $17,000-43,000. Most treatments have focused on either palliative care or accelerating the wound healing process through the application of growth factors (GF). Although growth factors, such as Palifermin, have shown promise in healing OM, they carrying the potential for neoplastic growths, and do not target the root cause of OM. The most commonly reported molecular mechanism for occurrence of OM is the excessive generation of reactive oxygen species (ROS) due to the anti-cancer chemo- radiation regimes. A potent antioxidant, such as curcumin, may represent an exciting therapeutic agent in OM prevention as a direct inhibitor of the earliest phase of OM development, i.e. oxidative stress. In fact, it can be applied before the anti-cancer regimes to prevent the occurrence of OM altogether. Additionally, curcumin: 1) has demonstrated ability to inhibit the growth of cancer cells and not trigger neoplastic growths, 2) has demonstrated wound healing capacity, 3) has proven anti-inflammatory and antimicrobial properties, 4) is well tolerated orally, and 5) is very inexpensive. However, delivery of curcumin physiologically represents a challenge due to its short half-life in physiological environments and poor aqueous solubility. The central hypothesis of this project is that curcumin-based polymers composed of natural antioxidants (C-PoNA) can be synthesized into tissue adhesive microparticles, and applied prophylactically to oral mucosal surfaces to decrease local cellular oxidative stress, and thereby decrease the likelihood of developing chemo/radio-therapy induced OM. As part of fulfilling this hypothesis, the research plan has been separated into two specific aims, Aim 1: C-PoNA microparticles provide controlled release of curcumin, and Aim 2: C-PoNA microparticles adhere to oral mucosal tissues. The first aim focuses on development and characterization of antioxidant polymer formulations, while the second aim focuses on demonstrating the ability to deliver select formulations to oral mucosal surfaces via an in vitro model. After the execution of this proposal, C-PoNA microparticle formulation(s) will be identified that can overcome the primary limitations of current curcumin delivery strategies. Microparticles that bond strongly to mucin while permitting long term local release will be obtained. In short, completion of this proposal will inform design of preclinical animal trials as e progress into phase II.

Public Health Relevance Statement:


Public Health Relevance:
This research will develop a new therapeutic strategy to prevent the occurrence of oral mucositis (OM). OM is a common side effect to the chemo-radiation treatment against head and neck cancers. These painful and debilitating mouth ulcers result in an increased treatment cost of $17,000 to $43,000 per patient. The proposed research plan will yield powdered formulations of biodegradable polymers of natural antioxidants that can be applied to the oral cavity via simple mouth rinses. The long term and local release of the potent antioxidant curcumin is expected to prevent the initiation of OM, thus drastically improving patient comfort and compliance, and preventing interruptions in the critically required anti-cancer therapy.

NIH Spending Category:
Cancer; Complementary and Alternative Medicine; Dental/Oral and Craniofacial Disease; Nutrition; Pain Conditions - Chronic; Pain Research; Prevention

Project Terms:
Acrylates; Address; Adherence (attribute); Adhesions; Adverse effects; Amines; Animals; Anti-Bacterial Agents; Anti-inflammatory; Anti-Inflammatory Agents; antimicrobial; Antioxidants; aqueous; base; biodegradable polymer; Biological; Cancer Cell Growth; cancer therapy; Caring; Cells; chemical cleavage; Chemistry; Compliance behavior; Complication; controlled release; cost; crosslink; cryogenics; Curcumin; cytotoxicity; design; Development; Drug Formulations; Economics; Environment; Esters; Gel; Generations; Growth Factor; Half-Life; Head and Neck Cancer; Healed; healing; Health Care Costs; improved; In Vitro; in vitro Model; inhibitor/antagonist; Injury; Interruption; keratinocyte growth factor; Kinetics; Lead; Life; Liquid substance; Lubricants; Malignant Neoplasms; Mechanics; Molecular; Mucins; Mucous Membrane; nano; Neoplasms; novel therapeutics; Oral; Oral cavity; oral mucositis; Oral mucous membrane structure; Oral Ulcer; oxidation; Oxidative Stress; Pain; Palliative Care; Particle Size; Patients; Pharmaceutical Preparations; Phase; Physiological; Plant Roots; Polymers; Powder dose form; pre-clinical; premature; prevent; Prevention; Process; Property; Protons; public health relevance; Radiation; Radio; Reaction; Reactive Oxygen Species; Reporting; Research; Severities; small molecule; Solubility; Speed (motion); Surface; Suspension substance; Suspensions; Technology; Therapeutic Agents; Thick; Time; Tissue Adhesives; Tissue Model; Tissues; Treatment Cost; treatment strategy; Uncertainty; United States; Vertebral column; wound; Wound Healing

Phase II

Contract Number: 2R44DE023523-02A1
Start Date: 4/1/13    Completed: 7/31/17
Phase II year
2016
(last award dollars: 2017)
Phase II Amount
$1,350,635

Oral mucositis (OM) is one of the most common side effects of most anti-cancer therapies, affecting nearly 100% of head and neck cancer patients (5-6% of the 12.7 million new cancer cases worldwide annually). OM manifests by deep and extremely painful mouth ulcers that can force patients to halt life-saving anti-cancer treatments and experience increased emergency room visits and longer hospital stays. Lubricating and analgesic mouth rinses are the primary treatment options but provide only palliative care and have shown poor efficacy. Palifermin (recombinant keratinocyte growth factor) is the only approved drug for treating OM in patients with hematological malignancies, but is not approved for solid tumors and carries the risk of neoplasia. Clearly, an unmet need exists for effective and safe drugs to treat this condition. Curcumin, a multi-action antioxidant and anti-inflammatory compound derived from turmeric, has been shown to reduce the incidence and severity of OM in preclinical studies and a recent human trial. Unfortunately, the trial required an aggressive dosing regimen of 4 mouth rinses every 4 hours, likely due to the known poor bioavailability of curcumin. Our innovation is a polymeric formulation that provides local and prolonged delivery of curcumin to buccal tissues, which will increase its efficacy in treating OM. Bluegrass Advanced Materials' product to treat OM will be a drug-device combination composed of (1) a sachet containing a single dose of poly(curcumin) powder and, (2) a wide-mouth bottle containing 5 ml of mucoadhesive solution. In Phase I, we demonstrated that biodegradable microparticles of poly(curcumin) can provide a sustained release of curcumin for 24 hours under physiological conditions while retaining antioxidant activity. In a preclinical study, we demonstrated that once-daily treatment with a poly(curcumin) oral rinse reduced the severity of OM in the Syrian hamster model. In Phase II, we propose to: 1. Optimize efficacy of poly(curcumin) oral rinse to treat radiation-induced OM. 2. Scale up manufacturing to produce pilot preclinical batch. 3. Develop combination product packaging in sachets and bottles and perform stability testing. 4. Demonstrate safety of poly(curcumin) oral rinse in GLP preclinical studies. Successful completion of Phase II will accomplish the key tasks necessary to prepare for Phase I human clinical trials and enable us to approach the FDA to begin the approval process.

Public Health Relevance Statement:


Public Health Relevance:
Oral mucositis (OM) is one of the most common side effects of most anti-cancer therapies, affecting nearly 500,000 new cancer patients every year in the US. OM, which manifests as deep and extremely painful mouth ulcers, forces patients to halt life-saving anti-cancer treatments and experience longer hospital stays. Bluegrass Advanced Materials' (BAM's) product to treat OM is a combination device composed of a sustained-release poly(curcumin) powder suspended in a viscous mucoadhesive solution, which can be mixed quickly and rinsed in the mouth by patients. The sustained and localized release of curcumin into the mouth tissue will target the key underlying mechanisms of OM, oxidative stress. Our product has the potential to greatly improve the quality of life of cancer patients.

NIH Spending Category:
Cancer; Complementary and Alternative Medicine; Dental/Oral and Craniofacial Disease; Pain Conditions - Chronic; Pain Research; Patient Safety

Project Terms:
Adverse effects; Affect; Air; Analgesics; Anti-inflammatory; Anti-Inflammatory Agents; Antioxidants; Biological Availability; biomaterial compatibility; Cancer Patient; cancer therapy; chemotherapy; Clinical Trials; Compliance behavior; Curcumin; cytotoxicity; Development; Devices; Disease; Dose; Drug Kinetics; effective therapy; Emergency department visit; Enteral Feeding; experience; Film; Formulation; Frequencies; Hamsters; head and neck cancer patient; Health Care Costs; Hematologic Neoplasms; Hour; Human; improved; Incidence; Infection; Inflammation; innovation; interest; Interruption; Intravenous; Investigational New Drug Application; irritation; keratinocyte growth factor; Laboratories; Length of Stay; Lidocaine; Life; Malignant Neoplasms; manufacturing scale-up; Mesocricetus auratus; Metabolism; Methods; Modeling; Mucositis; Narcotic Analgesics; Neoplasms; New Agents; Oral; Oral cavity; oral mucositis; Oral Ulcer; Outcome; Oxidative Stress; Oxygen; Pain; palliative; Palliative Care; Particle Size; Patients; Pharmaceutical Preparations; Phase; Physiological; Poa plant; Powder dose form; pre-clinical; preclinical study; Preparation; prevent; Process; Product Packaging; public health relevance; Quality of life; Radiation; Recombinants; Regimen; response; Risk; Safety; seal; Severities; Site; Solid Neoplasm; stability testing; standard of care; Supportive care; Suspension substance; Suspensions; systemic toxicity; Time; Tissues; Toxic effect; Tumeric; Viscosit